[31-501-pm] Pharmacotherapies (Clinical) 1

[31-501-pm05S] Factors influencing plasma disposition of osimertinib and their association with adverse events in patients with non-small cell lung cancer

○Natsu Hayashi¹, Michiaki Nakajo^2,4, Tomonobu Uchino^1,2,3, Kazuhiro Asada⁵, Yasuharu Yazawa^1,2, Takashi Osawa^1,2,3, Yoshiyuki Kagawa^1,2,3 (1. University of Shizuoka, 2. Grad. Sch. Pharm. Sci., University of Shizuoka, 3. Department of Clinical Research, Shizuoka General Hospital, 4. Department of Pharmacy, Shizuoka General Hospital, 5. Department of Respiratory medicine, Shizuoka General Hospital)